Skip to main content

Day: January 8, 2025

APA Corporation Announces Expiration and Final Results of Private Exchange Offers, Tender Offers, and Consent Solicitations and Waiver of Financing Condition

Written by Customer Service on . Posted in Public Companies.

HOUSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) — APA Corporation (“APA”) (Nasdaq: APA) announced today the final results as of 5:00 p.m., New York City time, on January 7, 2025 (the “Expiration Time”) of the previously announced (i) offers to exchange (the “Exchange Offers”) any and all validly tendered and accepted notes and debentures listed in the table below issued by Apache Corporation, its wholly-owned subsidiary (“Apache”), for new notes to be issued by APA (the “APA Notes”), (ii) offers to purchase for cash (the “Tender Offers” and together with the Exchange Offers, the “Offers”) up to $1,000,000,000 aggregate principal amount of any and all validly tendered and accepted Apache Notes of certain series (the “Apache Tender Notes”), and (iii) solicitations of consents (the “Consent Solicitations”) to certain proposed amendments (the...

Continue reading

Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

Written by Customer Service on . Posted in Mergers And Acquisitions.

All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder Value WARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development pipeline. The Company will seek acquisition targets to achieve the Company’s new corporate strategy. Windtree believes there is an opportunity in the market: the acquisition of small companies with FDA-approved...

Continue reading

SMC Entertainment Closes Acquisition of Boutique Investment Manager, Bateau Asset Management, Providing Entry to Australian and Southeast Asian Financial Services Markets

Written by Customer Service on . Posted in Mergers And Acquisitions.

Bateau Asset Management brings to SMC Entertainment:Foundational acquisition into International Financial Services Sector Well-established client base of high-net-worth individuals Experienced global client services team based in Australia and Singapore Research and advisory capabilities complementary to SMC Entertainment’s Fintech platformBOCA RATON, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) — SMC Entertainment, Inc. (“SMC” or the “Company”) (OTC PINK: SMCE), a Fintech incubator company focused on acquisition and support of commercialized financial services and technology (Fintech) companies, is pleased to announce that it has closed the Acquisition Agreement to acquire a 100% interest in Australia-based Bateau Asset Management, a boutique investment manager (“Bateau”). The acquisition will provide SMC with...

Continue reading

AXIL Brands Reports Second Quarter Fiscal Year 2025 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

LOS ANGELES, Jan. 08, 2025 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL” or the “Company”) (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, announces its financial and operational results for the second quarter ended November 30, 2024 (2Q25). Financial Highlights for the Quarter Ended November 30, 2024Revenue in 2Q25 was $7.7 million, as compared to $8.4 million in the prior year period Gross profit as a percentage of sales was 71.1% in 2Q25, as compared to 74.3% for the prior year period Operating expenses as a percentage of sales were 62.4% in 2Q25, as compared to 59.3% for the prior year period Net income in 2Q25 was $0.6 million, as compared to $1.0 million in the prior year period Adjusted EBITDA in 2Q25 was $1.0...

Continue reading

The Simply Good Foods Company Reports Fiscal First Quarter 2025 Financial Results and Reaffirms Fiscal Year 2025 Outlook

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today reported financial results for the thirteen weeks ended November 30, 2024. The acquisition of Only What You Need, Inc. (“OWYN”) was completed on June 13, 2024. Therefore, the Company’s year ago performance for the thirteen weeks ended November 25, 2023, does not include results of the OWYN business. The reference to “organic” or “legacy” Simply Good Foods in this press release encompasses Simply Good Foods’ business excluding OWYN. First Quarter Summary:(1)Net sales of $341.3 million versus $308.7 million Net income of $38.1 million versus $35.6 million Earnings per...

Continue reading

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

Written by Customer Service on . Posted in Public Companies.

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025. “We’re pleased to continue our work with the U.S. Department of Defense to supply BioThrax® to protect our nation’s service members who have a high risk of exposure to anthrax,” said Paul Williams, senior vice president, products head at Emergent. “This procurement ensures a continued supply of this important medical countermeasure to the U.S. military and demonstrates our commitment to delivering solutions that address...

Continue reading

23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology

Written by Customer Service on . Posted in Public Companies.

23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit, a technology company trusted by some of the world’s leading biomedical research organizations and governments. Discover23 provides analysis-ready genome-wide association studies (GWAS) conducted on 1000+ disease and condition cohorts curated from 4.7B phenotypic data points by 23andMe’s expert scientists. Biopharma...

Continue reading

GURU Organic Energy Announces Appointment of New Executive Vice President, Sales

Written by Customer Service on . Posted in Public Companies.

GURU Organic EnergyPatrick Charbonneau, Executive Vice President, Sales at GURUMONTRÉAL, Jan. 08, 2025 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company”), Canada’s leading organic energy drink brand1, is pleased to announce the appointment of Patrick Charbonneau as its new Executive Vice President, Sales. Patrick brings over 25 years of extensive experience in the food and beverage industry, further strengthening GURU’s executive leadership team. A visionary and charismatic leader, Patrick is known for his strategic acumen, operational excellence, and ability to inspire and build high-performing teams. During his successful tenure at PepsiCo Canada, he held three Vice President roles and delivered exceptional results by fostering collaborative, win-win partnerships with customers, distributors,...

Continue reading

Dentsply Sirona to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Written by Customer Service on . Posted in Public Companies.

CHARLOTTE, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 15, 2025, at 7:30 am PT (10:30 am ET). Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions...

Continue reading

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Written by Customer Service on . Posted in Dividend Reports And Estimates.

– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16th at 11:15 a.m. PT – TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2024. Profound anticipates total revenue for the fourth quarter of 2024 to be in the approximate range of $4.1 million to $4.2 million, representing year-over-year growth of between 105% and 110%, and sequential...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.